Twenty-year survival in glioblastoma: a case report and molecular profile.

Journal Article (Journal Article)

BACKGROUND: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. METHOD: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. RESULTS: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. CONCLUSION: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.

Full Text

Duke Authors

Cited Authors

  • Sperduto, CM; Chakravarti, A; Aldape, K; Burger, P; Papermaster, GB; Sperduto, P

Published Date

  • November 15, 2009

Published In

Volume / Issue

  • 75 / 4

Start / End Page

  • 1162 - 1165

PubMed ID

  • 19327897

Electronic International Standard Serial Number (EISSN)

  • 1879-355X

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2008.12.054


  • eng

Conference Location

  • United States